Education
About Us
Working with TipRanks
Follow Us
3D Medicines, Inc. (HK:1244)
:1244
1244 Stock Chart & Stats
HK$6.14
-HK$0.10(-2.80%)
At close: 4:00 PM EST
HK$6.14
-HK$0.10(-2.80%)
Day’s Range― - ―
52-Week RangeHK$2.71 - HK$10.02
Previous CloseN/A
Volume120.00K
Average Volume (3M)393.13K
Market Cap
HK$1.05B
Enterprise ValueHK$934.63M
Total Cash (Recent Filing)HK$447.10M
Total Debt (Recent Filing)HK$162.97M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding258,177,000
10 Day Avg. Volume535,000
30 Day Avg. Volume393,126
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.89
Price to Sales (P/S)1.56
P/FCF Ratio-2.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash PositionA strong cash and short-term investment base provides a durable runway for costly oncology R&D and clinical programs, reducing near-term refinancing pressure. This supports continued product development and strategic flexibility over the next several quarters.
Sustained Revenue Growth TrendConsistent top-line growth across multiple years indicates commercial traction for therapies and diagnostics, suggesting scalable demand. Sustained revenue expansion improves the probability of reaching operating leverage and eventual profitability if margins and costs are managed.
High Gross Profit MarginsElevated gross margins imply product-level pricing power and attractive unit economics for core therapies. If the firm can control SG&A and R&D spending or scale sales, high gross margins provide a structural path to durable profitability once operating efficiencies are realized.
Bears Say
Negative Operating And Free Cash FlowPersistently negative operating and free cash flow indicate the business cannot self-fund growth or clinical programs, increasing reliance on external capital. Over months this undermines financial flexibility and raises execution risk for long-duration drug development projects.
Persistent Net LossesOngoing net losses despite revenue gains point to structural cost or scale issues. Continued losses reduce retained earnings and can constrain reinvestment, requiring profitable inflection or material cost restructuring to achieve sustainable long-term financial health.
Reliance On External Financing And Past LeverageDependence on external funding and historical negative equity/high leverage heighten refinancing and dilution risks. Over a multi-month horizon this can constrain strategic choices, increase financing costs, and pressure management to prioritize cash generation over longer-term R&D investments.
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$2.71 and its highest was HK$10.02 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$1.05B.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Aug 29, 2025. The company reported -HK$0.392 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.392.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.392 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.993%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3D Medicines, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.03%
12-Months-Change
Fundamentals
Return on Equity
-21.45%
Trailing 12-Months
Asset Growth
-7.85%
Trailing 12-Months
Company Description
3D Medicines, Inc.
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
Technical Analysis
Brii Biosciences Limited
―
Genor Biopharma Holdings Limited
―
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Transcenta Holding Limited
―